Breakthrough In Cancer Treatment As This Rs 100 Drug Claims To Prevent Its Resurgence
The tablet, named 'R+Cu', contains pro-oxidant tablets with resveratrol and copper, which generate oxygen radicals in the stomach. It also reduces the side effects caused by chemotherapy by up to 50 per cent.
Researchers at the Tata Memorial Hospital in Mumbai have developed a drug that they claim can prevent the resurgence of cancer.
The tablet, named 'R+Cu', contains pro-oxidant tablets with resveratrol and copper, which generate oxygen radicals in the stomach, and cost just around Rs 100.
BCCL
The drug also reduces the side effects caused by chemotherapy by up to 50 per cent.
No human trials yet
However, it should be noted that the results are based on animal studies and no human trials have taken place so far.
According to reports, the tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI) and is expected to be available in the market by June-July.
How doctors have reacted
The new drug has however been met with mixed reactions among the medical fraternity.
UNSPLASH
The experimental mice study ¡°is not a substitute for established treatments, which continue to result in cures in a substantial proportion of cancer patients,¡± Dr Shyam Aggarwal, Chairman, Department of Medical Oncology, at Sir Ganga Ram Hospital told IANS.
Exaggerated claims
Dr. Rajeev Jayadevan, Co-Chairman National IMA COVID Task Force called it ¡°an exaggerated claim¡±.
"They used a pro-oxidant combination of copper and resveratrol (found in peanuts, cocoa, grapes) known to damage DNA by generating Oxygen radicals. Mice had less cfChPs after chemo while on this combination. Small study by the same researchers on 25 patients with myeloma. 20 patients got the nutraceutical (Cu-Resveratrol). They found no reduction in nausea, vomiting or diarrhea after chemotherapy for myeloma. However, reduced mucositis was reported," he pointed out.
Pexels
Breakthrough in medical research
Dr. Rahul Bhargava, Principal Director & Chief BMT, Fortis Memorial Research Institute, Gurugram, called it ¡°a great breakthrough in the field of medical research. Indian researchers are creating history. If the drug works, it will be a great benefit for cancer patients.¡±
¡°The tablet is promising and shows potential to be effective, but human trials are yet to be completed, which could take about five years,¡± he told IANS.
For more news and current affairs from around the world, please visit Indiatimes News.
Bobins Abraham is the Assistant News Editor at Indiatimes. He has more than twelve years of experience in TV and digital journalism. An avid student of history and geopolitics, he is a conservationist and environmentalist at heart. He writes on environment, sustainability, human-animal conflict and more.
Read More
